We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioSystem Development Launches its AssayMAP™ MAb Titer Assay
Product News

BioSystem Development Launches its AssayMAP™ MAb Titer Assay

BioSystem Development Launches its AssayMAP™ MAb Titer Assay
Product News

BioSystem Development Launches its AssayMAP™ MAb Titer Assay


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BioSystem Development Launches its AssayMAP™ MAb Titer Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioSystem Development, LLC. announces the release of the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples.

BioSystem Development says that antibody titer assays are a critical bottleneck in biotherapeutic process development. Although the current “gold standard” method – protein A affinity HPLC – is selective and sensitive, its throughput is severely limited to merely 4 – 12 samples an hour. The AssayMAP MAb Titer assay uses exactly the same chemistry as Protein A HPLC with a 100-fold increase in throughput, equivalent analytical performance and no need for specialized instrumentation.

AssayMAP cartridges, filled with POROS® MabCapture™ A media from Life Technologies Corporation, offer small-scale parallel analysis either manually in a spin-column format or on common automation platforms and measure IgG concentration across a wide range suited for process development without a need for sample dilution.

“This launch is a significant milestone in the evolution of the AssayMAP platform,” said Scott Fulton, founder and CEO. “It is the first assay we adapted to a spin-column format that requires only common lab equipment to perform, making AssayMAP solutions readily available for researchers when investment in new instrumentation platforms is not possible.”
Advertisement